Continuous Manufacturing Control Strategy Patents: Leaders & Trends 2026
Continuous Manufacturing Control Strategy Patents: Who Leads and Where the Field Is Still Open
43.0% concentration. The top 5 assignees hold 335 of 779 records in scope — filing here is already concentrated at the top rather than spread evenly. Filings climbed from 35 in 2017 to a peak of 132 in 2023, with the 2021→2024 span alone showing +155% growth (20 to 51 records). 2025 and 2026 figures are still filling in as publications catch up with filing dates, so they should not be read as a slowdown.
- 1REGENERON PHARMACEUTICALS INC98
- 2VERTEX PHARMACEUTICALS INC78
- 3GENZYME CORP74
- 4FISHER ROSEMOUNT SYST INC63
- 5CONTINUUS PHARMACEUTICALS INC22
See the full continuous manufacturing control strategy analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in continuous manufacturing control strategy?
One assignee leads the ranked field with 98 records, well ahead of the fifth-place holder at 22 and the tenth-place holder at 15. The top 5 assignees combined account for 43.0% of all 779 records in scope, and the top 10 combined reach 53.5%. That gap between the leader and the rest indicates a company running a sustained filing programme rather than occasional defensive filings, so competitive tracking should watch that leader’s claim language closely.
How fast is patent filing growing in this space?
Filing volume rose from 20 records in 2021 to 51 in 2024, a +155% increase over that three-year span, with the highest single year so far being 2023 at 132 records. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures are still incomplete and should not be read as the trend slowing down. The reliable growth read stops at 2024.
What technology areas dominate the claims in this field?
Material analysis and testing (IPC class G01N) covers the largest share at 24.9% of the 779 records, followed by bioreactor and enzyme apparatus (C12M) at 21.6% and peptide/protein chemistry (C07K) at 20.5%. Control and regulating systems (G05B) sit lower at 15.8%, meaning the sensing and material-analysis layer is more heavily claimed than the control-logic layer itself. Because records often carry multiple IPC codes, these percentages overlap rather than summing to 100%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Continuous Manufacturing Control Strategy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.